AdaptivCRT Algorithm Put To The Test In Medtronic’s Superiority Trial
This article was originally published in The Gray Sheet
Executive Summary
The first of a planned 3,000 patients have been enrolled in the AdaptResonse trial of Medtronic’s AdaptivCRT cardiac resynchronization algorithm. Previous studies have shown the algorithm reduces hospitalizations, and Medtronic hopes AdaptResponse will show it reduces mortality and medical interventions.
You may also be interested in...
Medtronic Claims Clinical, Cost Advantages For Just-Launched Viva CRT-D
Viva is the first of Medtronic’s U.S. CRT-Ds to incorporate the proprietary AdaptivCRT algorithm designed to more readily adapt to a patient’s condition and optimize therapy. The firm also launched its Evera ICD last week.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.